Cibus (CBUS) Change In Receivables : $1.58 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Cibus Change In Receivables?

Cibus's change in receivables for the quarter that ended in Mar. 2024 was $-0.12 Mil. It means Cibus's Accounts Receivable increased by $0.12 Mil from Dec. 2023 to Mar. 2024 .

Cibus's change in receivables for the fiscal year that ended in Dec. 2023 was $1.70 Mil. It means Cibus's Accounts Receivable declined by $1.70 Mil from Dec. 2022 to Dec. 2023 .

Cibus's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.65 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Cibus's Days Sales Outstanding for the three months ended in Mar. 2024 was 108.83.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cibus's liquidation value for the three months ended in Mar. 2024 was $-188.21 Mil.

Cibus Change In Receivables Historical Data

The historical data trend for Cibus's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cibus Change In Receivables Chart

Cibus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-1.12

-3.77

4.89

1.70

Cibus Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	1.38	0.30	0.03	-0.12

Cibus Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.58 Mil.

Cibus (NAS:CBUS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cibus's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.65	/	0.545	*	91
=	108.83

2. In Ben Graham's calculation of liquidation value, Cibus's accounts receivable are only considered to be worth 75% of book value:

Cibus's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	24.507	-	213.207	+	0.75 * 0.65	+	0.5 * 0
=	-188.21

Cibus Change In Receivables Related Terms

Thank you for viewing the detailed overview of Cibus's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Cibus (CBUS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cibus Inc (NAS:CBUS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

6455 Nancy Ridge Drive, San Diego, CA, USA, 92121

Website

https://www.cibus.com

Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies.

Executives

Rory B Riggs	director, officer: Chief Executive Officer	65 RAILROAD AVE, RIDGEFIELD NJ 07657
Collins James C. Jr.	director	1007 MARKET STREET, D-9058, WILMINGTON DE 19898
Jonathan Finn	10 percent owner	C/O VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Gerhard Prante	director	SCHONE AUSSICHT 5, HOFHEIM A. TS 2M 65719
Mark Terrence Finn	director	VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Jean-pierre Jules Lehmann	director	21 ALPINASTRASSE, CH 3780, GSTAAD V8 3780
Keith Allen Walker	director	13315 ROXTON CIRCLE, SAN DIEGO CA 92130
Wade Hampton King	officer: Chief Financial Officer	750 MEADOWOOD DRIVE, ASPEN CO 81611
Gocal Gregory Francis William	officer: See Remarks	13737 BASSMORE DR., SAN DIEGO CA 92129
Peter Beetham	director, officer: See Remarks	6455 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Yves J Ribeill	director	C/O CALYXT, INC., 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Michael A. Carr	director, officer: President and CEO	2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
William Koschak	officer: Chief Financial Officer	2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Sarah Reiter	officer: Chief Business Officer	202 COUSTEAU PLACE, DAVIS CA 95618
Daniel F Voytas	officer: Chief Science Officer	2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113